Patent ID: 8163931

Claim:
A method for the treatment of a disease selected from the group consisting of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, conjunctivitis, allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, mastocytosis, hyper IgE syndrome, systemic lupus erythematosus, acne, multiple sclerosis, allograft rejection, chronic obstructive pulmonary disease, rheumatoid arthritis, psoriatic arthritis and osteoarthritis, comprising administering to a patient in need of such treatment an effective amount of a compound of general formula (I): wherein R 1 , R 3 and R 4 are independently hydrogen, halo, C 1 -C 6 alkyl, —O(C 1 -C 6 alkyl), —CON(R 11 ) 2 , —SOR 11 , —SO 2 R 11 , —SO 2 N(R 11 ) 2 , —N(R 11 ) 2 , —NR 11 COR 11 , —CO 2 R 11 , —COR 11 , —SR 11 , —OH, —NO 2 or —CN; each R 11 is independently hydrogen or C 1 -C 6 alkyl; R 2 is halogen; R 5 and R 6 are each independently hydrogen, or C 1 -C 6 alkyl or together with the carbon atom to which they are attached form a C 3 -C 7 cycloalkyl group; R 7 is methyl; R 8 is a phenyl, naphthalenyl, quinolinyl, quinoxalinyl, thiazolyl, or biphenyl, any of which is optionally substituted with one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, —O(C 1 -C 6 )alkyl, —CON(R 11 ) 2 , —SOR 11 , —SO 2 R 11 , —SO 2 N(R 11 ) 2 , —N(R 11 ) 2 , —NR 11 COR 11 , —CO 2 R 11 , —COR 11 , —SR 11 , —OH, —NO 2 —CN; wherein R 11 is as defined above; R 9 is hydrogen, or C 1 -C 6 alkyl; provided that: R 8 is not phenyl substituted with —COOH; or a pharmaceutically acceptable salt thereof.